Literature DB >> 11042151

Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene.

D A Nickerson1, S L Taylor, S M Fullerton, K M Weiss, A G Clark, J H Stengård, V Salomaa, E Boerwinkle, C F Sing.   

Abstract

A common strategy for genotyping large samples begins with the characterization of human single nucleotide polymorphisms (SNPs) by sequencing candidate regions in a small sample for SNP discovery. This is usually followed by typing in a large sample those sites observed to vary in a smaller sample. We present results from a systematic investigation of variation at the human apolipoprotein E locus (APOE), as well as the evaluation of the two-tiered sampling strategy based on these data. We sequenced 5.5 kb spanning the entire APOE genomic region in a core sample of 72 individuals, including 24 each of African-Americans from Jackson, Mississippi; European-Americans from Rochester, Minnesota; and Europeans from North Karelia, Finland. This sequence survey detected 21 SNPs and 1 multiallelic indel, 14 of which had not been previously reported. Alleles varied in relative frequency among the populations, and 10 sites were polymorphic in only a single population sample. Oligonucleotide ligation assays (OLA) were developed for 20 of these sites (omitting the indel and a closely-linked SNP). These were then scored in 2179 individuals sampled from the same three populations (n = 843, 884, and 452, respectively). Relative allele frequencies were generally consistent with estimates from the core sample, although variation was found in some populations in the larger sample at SNPs that were monomorphic in the corresponding smaller core sample. Site variation in the larger samples showed no systematic deviation from Hardy-Weinberg expectation. The large OLA sample clearly showed that variation in many, but not all, of OLA-typed SNPs is significantly correlated with the classical protein-coding variants, implying that there may be important substructure within the classical epsilon 2, epsilon 3, and epsilon 4 alleles. Comparison of the levels and patterns of polymorphism in the core samples with those estimated for the OLA-typed samples shows how nucleotide diversity is underestimated when only a subset of sites are typed and underscores the importance of adequate population sampling at the polymorphism discovery stage. [The sequence data described in this paper have been submitted to the GenBank data library under accession no. AF261279.]

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042151      PMCID: PMC310963          DOI: 10.1101/gr.146900

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  58 in total

1.  Circumventing multiple testing: a multilocus Monte Carlo approach to testing for association.

Authors:  L M McIntyre; E R Martin; K L Simonsen; N L Kaplan
Journal:  Genet Epidemiol       Date:  2000-07       Impact factor: 2.135

2.  PipMaker--a web server for aligning two genomic DNA sequences.

Authors:  S Schwartz; Z Zhang; K A Frazer; A Smit; C Riemer; J Bouck; R Gibbs; R Hardison; W Miller
Journal:  Genome Res       Date:  2000-04       Impact factor: 9.043

Review 3.  Adjusting the focus on human variation.

Authors:  M Przeworski; R R Hudson; A Di Rienzo
Journal:  Trends Genet       Date:  2000-07       Impact factor: 11.639

4.  On the number of segregating sites in genetical models without recombination.

Authors:  G A Watterson
Journal:  Theor Popul Biol       Date:  1975-04       Impact factor: 1.570

5.  Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism.

Authors:  S M Fullerton; A G Clark; K M Weiss; D A Nickerson; S L Taylor; J H Stengârd; V Salomaa; E Vartiainen; M Perola; E Boerwinkle; C F Sing
Journal:  Am J Hum Genet       Date:  2000-09-13       Impact factor: 11.025

6.  SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.

Authors:  E R Martin; E H Lai; J R Gilbert; A R Rogala; A J Afshari; J Riley; K L Finch; J F Stevens; K J Livak; B D Slotterbeck; S H Slifer; L L Warren; P M Conneally; D E Schmechel; I Purvis; M A Pericak-Vance; A D Roses; J M Vance
Journal:  Am J Hum Genet       Date:  2000-06-21       Impact factor: 11.025

Review 7.  Apolipoprotein E and atherosclerosis: insight from animal and human studies.

Authors:  J Davignon; J S Cohn; L Mabile; L Bernier
Journal:  Clin Chim Acta       Date:  1999-08       Impact factor: 3.786

8.  Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men.

Authors:  J H Stengård; K E Zerba; J Pekkanen; C Ehnholm; A Nissinen; C F Sing
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

9.  Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements.

Authors:  J D Smith; A Melián; T Leff; J L Breslow
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

10.  Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3.

Authors:  R J Havel; L Kotite; J P Kane; P Tun; T Bersot
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

View more
  49 in total

1.  Genotyping single nucleotide polymorphisms directly from genomic DNA by invasive cleavage reaction on microspheres.

Authors:  Kakuturu V N Rao; Priscilla Wilkins Stevens; Jeff G Hall; Victor Lyamichev; Bruce P Neri; David M Kelso
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

2.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

Review 3.  "Are we there yet?": Deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits.

Authors:  Grier P Page; Varghese George; Rodney C Go; Patricia Z Page; David B Allison
Journal:  Am J Hum Genet       Date:  2003-09-17       Impact factor: 11.025

4.  Optimal haplotype block-free selection of tagging SNPs for genome-wide association studies.

Authors:  Bjarni V Halldórsson; Vineet Bafna; Ross Lippert; Russell Schwartz; Francisco M De La Vega; Andrew G Clark; Sorin Istrail
Journal:  Genome Res       Date:  2004-08       Impact factor: 9.043

5.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

6.  Identifying disease polymorphisms from case-control genetic association data.

Authors:  L Park
Journal:  Genetica       Date:  2010-10-14       Impact factor: 1.082

7.  GERBIL: Genotype resolution and block identification using likelihood.

Authors:  Gad Kimmel; Ron Shamir
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

8.  A fast method for computing high-significance disease association in large population-based studies.

Authors:  Gad Kimmel; Ron Shamir
Journal:  Am J Hum Genet       Date:  2006-07-24       Impact factor: 11.025

9.  Sequence variation and linkage disequilibrium in the human T-cell receptor beta (TCRB) locus.

Authors:  L Subrahmanyan; M A Eberle; A G Clark; L Kruglyak; D A Nickerson
Journal:  Am J Hum Genet       Date:  2001-06-29       Impact factor: 11.025

10.  Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism.

Authors:  Jari H Stengård; Andrew G Clark; Kenneth M Weiss; Sharon Kardia; Deborah A Nickerson; Veikko Salomaa; Christian Ehnholm; Eric Boerwinkle; Charles F Sing
Journal:  Am J Hum Genet       Date:  2002-08-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.